Lotanna Ezeja, BPharm

Auburn University
Auburn, Alabama, United States

Disclosure information not submitted.

Presentation(s):

• 6D-11 - Post-Marketing Safety of Lantus Insulin Glargine and its Interchangeable Biosimilar Semglee in the United States: A Disproportionality Analysis using the FDA Adverse Event Reporting System (FAERS) Database

  Tuesday, August 26, 2025
  2:40 PM - 2:45 PM ET